Biotech Breakthroughs aims to achieve market-thumping returns by investing at the cutting edge of genomics, gene therapies, cell therapies, and other emerging biotechnologies. We're not simply crossing our fingers and gambling on the outcomes of clinical trials; rather, we are constructing a portfolio that balances risk and reward in a way we expect to offer exceptional performance with acceptable risk.